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Abstract
Classically, HLA-DR expressed on antigen presenting cells (APC) initiates lymphocyte activation via presentation of peptides to
TCR bearing CD4+ T-Cells. Here we demonstrate that HLA-DR alpha 2 domain (sHLA-DRa2) also induces negative signals by
engaging TIRC7 on lymphocytes. This interaction inhibits proliferation and induces apoptosis in CD4+ and CD8+ T-cells via
activation of the intrinsic pathway. Proliferation inhibition is associated with SHP-1 recruitment by TIRC7, decreased
phosphorylation of STAT4, TCR-f chain & ZAP70, and inhibition of IFN-c and FasL expression. HLA-DRa2a n dT I R C 7c o - l o c a l i z ea t
the APC-T cell interaction site. Triggering HLA-DR - TIRC7 pathway demonstrates that sHLA-DRa2 treatment inhibits
proinflammatory-inflammatory cytokine expression in APC & T cells after lipopolysaccaride (LPS) stimulation in vitro and induces
apoptosis in vivo. These results suggest a novel antiproliferative role for HLA-DR mediated via TIRC7, revise the notion of an
exclusive stimulatory interaction of HLA-DR with CD4+ T cells and highlights a novel physiologically relevant regulatory pathway.
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Introduction
TIRC7 (TCIRG1) is a seven transmembrane protein induced
early after allo-activation of human lymphocytes [1,2]. Targeting
of TIRC7 with antibodies decreased IL-2 transcription and
inhibited the release of IFN-c, but not IL-10 in vitro and in vivo
[1–3]. Cell surface expression profiles and results obtained from
antibody blocking studies suggested that TIRC7 interacts with a
ligand at the cell surface. Here we report that the HLA-DR alpha
2 domain is a ligand for TIRC7. HLA-DR molecule consists of an
alpha and beta chain expressed on antigen presenting cells and
activated T cells. Binding of HLA-DR to T cell receptor on CD4+
T cells is known to initiate immune activation and accordingly
HLA-DR molecules are considered to be immune stimulatory.
We extend this view by providing evidence for an important
novel negative regulatory role of HLA-DR executed via binding
with its non-polymorphic alpha 2 domain to TIRC7, a negative
regulator of immune activation expressed on activated lympho-
cytes. Binding of HLA-DR alpha 2 to TIRC7 delivers antipro-
liferative signals to lymphocytes which is not solely restricted to
CD4+ cells. Induction of the HLA-DR alpha 2 - TIRC7 pathway
leads to activation of the intrinsic apoptotic pathway resulting in
apoptosis of CD4+ and CD8+ lymphocytes. The downregulatory
mechanism of the immune response is associated with SHP-1
recruitment and include the inhibition IFN-c expression, phos-
phorylation of STAT4, TCR-f chain, ZAP70 and expression of
FasL in T cells. Ligation of TIRC7 using soluble HLA-DRa2
(sHLA-DRa2) causes apoptosis in lymphocytes via activation of
caspase 9 and 7. TIRC7 and HLA-DR are co-localized at the site
of T cell - APC interaction. Accordingly, targeting of TIRC7 with
sHLA-DRa2 controls proinflammatory cytokine release in APC
and T cells in vitro. Physiological relevance of TIRC7 and HLA-
DR a2 binding is shown in acute inflammatory setting in vivo after
LPS. Treatment of mice with sHLA-DRa2 inhibits APC and T
cell cytokine expression and induces apoptosis in vivo underlining
the physiological importance of TIRC7-HLA-DR alpha 2
binding. Notably, the modulation of the HLA-DR alpha 2 -
TIRC7 pathway in vivo allows to reduce significantly the
inflammatory response and cytokine release induced by APC-T
cell interaction during immune activation. Thus, our results
demonstrate that binding of HLA-DR alpha 2 to TIRC7 at the
APC-T cell interaction side provides negative signalling events
during immune activation leading to downregulation of the
immune response.
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TIRC7 protein binds to the alpha 2 domain of HLA-DR
molecule
To investigate the ligand(s) interacting with TIRC7 we
established a yeast two-hybrid screen using a cDNA library of
allo-activated human peripheral blood lymphocytes (PBL). Con-
structs of the N-terminal, C-terminal sequence stretch, and large
extracellular loop of TIRC7 were fused to a Gal4-binding domain
and used as bait. While there were no interactions found with the
N-terminal or C-terminal domains of TIRC7, a clone interacting
with the large extracellular loop of TIRC7 was identified which
contained the sequence of human HLA-DR alpha 2 (Figure 1A).
This binding was confirmed by an anti-TIRC7 mAb co-
precipitating HLA-DR alpha 2 from lysates obtained from allo-
activated PBL, using specific anti-HLA-DR mAb for immuno-
blotting. In contrast, in lysates of the Jurkat cell line which is not
expressing HLA-DR anti-TIRC7 mAb only TIRC7 was precip-
itated (Figure 1B). Similar results were obtained utilizing a
polyclonal antibody recognizing TIRC7 [1] which also co-
precipitated HLA-DR alpha chain as confirmed by protein
sequencing (data not shown).
Figure 1. HLA-DR alpha 2 domain interacts with TIRC7 protein. A. Strain AH109 carrying GAL4 activation domain, fused to cDNA containing
HLA-DR, was tested for interaction with indicated domains of TIRC7 (N-terminus aa 1-173, large extracellular domain aa 438-512 or C-terminus aa 586-
614) as bait. The growth of combined clones on Histidine-negative agar plates indicate a specific interaction between the HLA-DR alpha 2 and TIRC7
extracellular domain whereas no interaction between HLA-DR alpha 2 to the C – terminal or N- terminal domain of TIRC7 was observed. The growth
of colonies on Histidine positive agar plates which represents a positive control, is shown in the left panel. B. Lysates were prepared from 1 h allo-
activated PBL and Jurkat cells. Lysates were immunoprecipitated (IP) with anti-TIRC7 mAb and immunoblotted (IB) with specific antibody against
HLA-DR protein or TIRC7 in denaturing conditions. Co-precipitation of TIRC7 and HLA-DR is observed in PBL whereas only TIRC7 was precipitated in
HLA-DR negative Jurkat cells. C. COS7 cells were transiently transfected with a TIRC7-myc fusion protein vector construct, incubated with sHLA-DRa2
and stained with secondary anti-human Fc protein-Cy3 conjugated mAb. Flow cytometry analysis revealed that sHLA-DRa2 solely binds to TIRC7
transfected COS7 cells and fail to bind to non-transfected COS7 control cells. Shown is one experiment out of four. D. COS7 cells transfected with
TIRC7-myc fusion protein showed concentration-dependent binding of sHLA-DRa2 (0, 25, 50, 150 mg/ml) using direct immunofluorescence method.
No binding of control protein was observed in transfected COS7 cells. Shown is one experiment out of three. E and F. TIRC7 deficient and wild-type
mouse splenocytes were isolated and either stimulated with PHA for 48 h or remained unstimulated. Cells were incubated with either human HLA-DR
alpha 2 or human control protein prior to flow cytometry (E) or confocal microscopic analysis (F) using anti-human Fc-specific Cy3 as secondary
antibody. The results show that HLA-DR alpha 2 solely binds to stimulated WT cells in flow cytometric and microscopic analyses. Shown is one
experiment out of three, respectively.
doi:10.1371/journal.pone.0001576.g001
HLA-DR Alpha 2
PLoS ONE | www.plosone.org 2 February 2008 | Volume 3 | Issue 2 | e1576Soluble HLA-DR alpha 2 specifically binds to TIRC7 and
the interaction modulates IFN-c expression and STAT4
signaling
The ability of HLA-DR alpha 2 to interact with TIRC7 was
further analysed in binding studies using a soluble HLA-DR alpha
2 fusion protein consisting of the entire human HLA-DR alpha 2
domain linked to an IgG1 Fc protein and expressed in COS7 cells.
The ability of sHLA-DRa2 to bind to TIRC7 expressed on the cell
membrane was tested in COS7 cells which were transiently
transfected with a TIRC7 cDNA fused to a myc-tagged expression
vector at the extracellular carboxy terminus [1]. Flow cytometry
using an anti-Fc protein antibody revealed that human sHLA-
DRa2 exclusively bound to the surface of TIRC7-expressing
COS7 cells whereas no binding was observed in non-transfected
control COS7 cells (Figure 1C). The binding of sHLA-DRa2t o
TIRC7 expressed in COS7 cells was shown to be concentration-
dependent (Figure 1D). The binding specificity was confirmed
when splenocytes of wild-type and TIRC7 deficient mice were
stimulated with PHA and incubated in the presence and absence
of sHLA-DRa2. Flow cytometry and microscopy revealed that
sHLA-DRa2 binds solely to splenocytes from wild type mice
whereas no binding was observed on splenocytes from TIRC7
deficient mice (Figure 1E and F).
To examine whether interaction of HLA-DR alpha 2 and TIRC7
results in modulation of cellular responses upon cell activation we
studied the effect of sHLA-DRa2 on cytokine expression in PBL
activated for 48h with PHA. Incubation of lymphocytes with sHLA-
DRa2 resulted in significant inhibition of IFN-c (Figure 2A). In
contrast, IL-10 expression was not affected (Figure 2B). The IFN-c
response is regulated by transcription factors of the STAT (signal
transducers and activators of transcription) family [4]. Specifically,
STAT4 regulates IFN-c responses whereas STAT6 has been
demonstrated to be involved in the regulation of IL-10 or IL-4
expression [5]. To examine whether the inhibitory response induced
by sHLA-DRa2 crosslinking to TIRC7 involves STAT4 and
STAT6, human PBL were stimulated with allo-antigen, cultured
with sHLA-DRa2 and lysates were analyzed for phosphorylation of
STAT4 and STAT6 proteins by Western blot analysis. Indeed,
STAT4 phosphorylation was decreased in the presence of sHLA-
Figure 2. Soluble HLA-DR alpha 2 domain inhibits IFN-c cytokine expression and phosphorylation of STAT4, but not STAT6. A.
Human PBL were activated with PHA for 48 h and co-cultured with either sHLA-DRa2 or control protein. Supernatants were subjected to quantitative
sandwich ELISA. sHLA-DRa2 at a concentration of 50 mg/ml significantly inhibited the IFN-c expression of stimulated PBL, whereas control protein
exhibited no significant effect. B. No inhibition of IL-10 expression was observed. The results shown represent the means of five independent
experiments, respectively. C. Human PBL were allo-activated for 4 h in the presence of anti-TIRC7 mAb and subjected to Western blot analysis. Equal
volume of cells were fractionated by SDS-PAGE, and the phosphorylation status of STAT4 and STAT6 was determined by Western blot analysis. STAT4
phosphorylation was decreased in the presence of sHLA-DRa2 whereas pSTAT6 remained unchanged. No changes were observed using STAT4, and
anti-Tubulin mAb. Shown is one representative experiment out of three independent experiments. D. Human PBL were isolated using standard Ficoll
gradient centrifugation protocol. Cells were activated with PHA, anti-CD3/CD28 mAb, and MLR, respectively, and co-cultured with either sHLA-DRa2
or control protein in varying concentrations (50, 100, and 150 mg/ml). Cells were subjected to CFSE proliferation assays. A significant inhibition of
proliferation was observed using sHLA-DRa2 in all proliferation assays whereas the control protein did not show any inhibition. The results shown
represent the means of four independent experiments, respectively. E. The inhibition of proliferation of 48 h anti-CD3/CD28 stimulated human PBL
by sHLA-DRa2 (100 mg/ml) was prevented by co-incubation of the anti-TIRC7 mAb 136 (100 mg/ml). F. Cell lysates were prepared from 1 h allo-
activated PBL and immunoprecipitated (IP) with anti-TIRC7 mAb and subjected to western blot analysis. The immunoblot (IB) with anti-TIRC7 and
anti-SHP-1 mAb showed the co-precipitation of SHP-1 and TIRC7. G. The phosphorylation of TCR-f chain and ZAP70 induced by IL-2 is inhibited by
sHLA-DRa2. Human PBL were isolated and activated using anti-CD3/CD28 mAb for 18 h in the presence and absence of sHLA-DRa2. In the presence
of sHLA-DRa2 (50 mg/ml) the phosphorylation of TCR-f chain and ZAP70 in stimulated cells (right lane) was reduced to a level similar to that of non-
stimulated cells (left lane) while in stimulated cells without sHLA-DRa2 (middle lane) substantial phosphorylation of both proteins was observed.
doi:10.1371/journal.pone.0001576.g002
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allostimulation of human lymphocytes (Figure 2C).
Interaction of sHLA-DRa2 and TIRC7 inhibits proliferation
and results in decreased phosphorylation of TCR
associated signaling molecules
To further examine cellular responses induced by the interaction
of HLA-DR alpha 2 and TIRC7, we studied the effect of sHLA-
DRa2 on proliferation of human lymphocytes stimulated by PHA,
anti-CD3/CD28, and alloactivation (mixed lymphocyte culture,
MLR), respectively. As determined by BrdU incorporation,
incubation of lymphocytes with sHLA-DRa2r e s u l t e di na
concentration-dependent inhibition of proliferation in these prolif-
eration assays (Figure 2D). To demonstrate the specificity of HLA-
DRa2 binding to TIRC7 a displacement ELISA was performed
using an anti-TIRC7 monoclonal antibody (mAb136) which was
generated by immunization of mice with TIRC7 protein. This
antibody binds specifically to TIRC7 and prevents binding between
TIRC7 and HLA-DR as observed in Elisa assays (data not shown).
The antiproliferative signals induced by binding of sHLA-DRa2t o
TIRC7 in human lymphocytes were prevented by blocking the
binding of sHLA-DRa2 to TIRC7 using mAb 136 (Figure 2E). The
inhibitory effects induced by TIRC7 ligation could be mediated by
the recruitment of the phosphotyrosine phosphatase SHP-1 which
plays an important negative regulator role on lymphocyte signaling
pathways for a variety ofreceptors involved inlymphocyteactivation
[6–9]. SHP-1 was shown to bind via the ITIM (immunoreceptor
tyrosine-based inhibitory motif) motif to cell surface molecules with
signaling capacity resulting in the down-regulation or termination of
signal transduction events [8,9]. The hypothesis that SHP-1 might
be involved in TIRC7 signaling was based on the fact that an ITIM
motif (VIYKWL, aa 371-377) was identified within the TIRC7
protein which would potentially allow for the recruitment of SHP-1.
Using an anti-TIRC7 mAb, immune precipitation of lysates from
allo-activated PBL revealed co-precipitation of TIRC7 and SHP-1
(Figure 2F). Thus, the recruitment of SHP-1 by TIRC7 upon cell
activation is a possible mechanism for the down-regulation of
signaling events. SHP-1 was previously demonstrated to induce the
dephosphorylation of ZAP70 causing an inhibition of proximal
TCR-induced signaling events [10,11]. To examine whether the
interaction of HLA-DR alpha 2 and TIRC7 affects the phosphor-
ylation of ZAP70 and the TCR-f chain, freshly isolated human PBL
were alloactivated in the presence or absence of sHLA-DR a2a n d
subjected to immunoblot analysis. Indeed, the phosphorylation of
TCR-f chain and ZAP70 were found to be decreased to a level
similar to that of non-activated cells, whereas the expected
phosphorylation was observed in activated lymphocytes not treated
with sHLA-DRa2 (Figure 2G). These results indicate that the
mechanisms which lead to an inhibition of cell proliferation by the
interaction of HLA-DRalpha 2 and TIRC7 involve proximal TCR-
induced signaling events.
Interaction of sHLA-DRa2 with TIRC7 expressed in CD4+
and CD8+ T cells results in cell cycle arrest and apoptosis
in lymphocytes
In addition to the induction of anergy and inhibition of
proliferative response, cell cycle arrest as well as apoptosis are
further important mechanisms to control the activation of
lymphocytes [12]. To examine whether the antiproliferative effect
induced by sHLA-DRa2 crosslinking to TIRC7 involve these
mechanisms as well human PBL were stimulated with anti-CD3/
CD28 antibodies in the presence of sHLA-DRa2 or control
protein, and analyzed for cell cycle arrest and apoptosis using flow
cytometric analysis. Flow cytometry profiles of PBL illustrate that,
as a result of stimulation, 25% of the lymphocytes proceeded into
the G2/S phase (Figure 3A). In contrast, targeting of TIRC7 with
sHLA-DR a2 led to a dramatic reduction of the cell number in
G2/S phase as most of the cells prevailed in G0/G1 cell cycle
phase (89%) (Figure 3A) which is indicative for cell cycle arrest.
Moreover, 72 h after incubation of the cells with sHLA-DRa2a n
increased number of cells (46,4%) belonged to the subdiploid
population, indicating that cells were apoptotic and died as a
consequence of TIRC7 engagement (Figure 3B).
It is well known that HLA-DR molecules interact with CD4 + T
cells. Yet from the above results we concluded that HLA-DR
protein, especially the alpha 2 domain may induce apoptosis also
in CD8+ cells. To examine this hypothesis CD4+ and CD8+ cells
were separated by magnetic beads and stimulated 72 h by anti-
CD3/CD28 antibodies in the presence and absence of sHLA-DR
a2. The results illustrate that compared with non-treated controls
sHLA-DRa2 binding leads to induction of apoptosis in both,
CD4+ (51%) and CD8+ (54%) cells (Figure 3C).
Since interaction of HLA-DR especially with CD8+ T cells has
not been described so far, we analyzed the HLA-DRa2 binding to
CD8+ and CD4+ T cells. Confocal microscopy illustrates that
sHLA-DRa2 exhibits a similar binding pattern on CD4+ (30–
40%) and CD8+ (40–50%) cells (Figure 4) as was observed with
anti-TIRC7 antibody [1]. No binding was observed in any control
experiments, thus, sHLA-DRa2 binds specifically to CD4+ and
CD8+ T cells leading to apoptosis in both subsets.
Targeting of TIRC7 leads to apoptosis via the activation
of the intrinsic apoptotic pathway in lymphocytes
Proteins central to apoptosis are members of the caspase family
which can be divided into initiator (caspase 8 and 9) and effector
(caspase7and3)caspases[13].Intheintrinsicpathwaytheapoptosis
is mediated by mitochondria whereas the extracellular death
receptor, FasL, mediates the extrinsic pathway [13,14]. To analyze
the mechanistic details, human PBL was used to test the caspase
activity after 5 h of TIRC7 targeting using sHLA-DRa2. Caspase 9
was activated as was indicated by an increase of the cleaved product
in the presence of sHLA-DRa2 whereas no activation of caspase 8
was observed in PBL (Figure 5A). Analysis of caspase 7 showed an
increase of the cleaved product of 20kDa size upon TIRC7 ligation,
while an activation of caspase 3 was not observed (Figure 5A). To
analyze whether TIRC7-dependent apoptosis can be reversed by
adding inhibitor of caspase 9 to the cultures, incubation of cells with
the caspase 9 inhibitor z-LEH-fmk reduced TIRC7-dependent
apoptosis to normal levels (data not shown). Although no activation
of caspase 8 was observed after sHLA-DRa2 ligation, modulation of
theFasLexpressiononTcellswasanalyzed.Flowcytometryanalysis
of PBL activated with anti-CD3/CD28 antibody for 24 h in the
presence of the sHLA-DRa2 revealed a remarkably reduced
expression of FasL at the cell surface of human T cells (Figure 5B, d).
These results are in agreement with a down-regulatory effect of
TIRC7 on ZAP70 activity, since ZAP70 was shown to be essential
for the regulation of FasL expression on the surface of activated T
cells [11] and indicate that TIRC7 mediated modulation of the
proliferative response in PBL involves the intrinsic, mitochondrial
pathway via caspase 9.
HLA-DR co-localizes with TIRC7 at the APC-T cell interface
and soluble HLA-DRa2 prevents APC mediated T cell
cytokine release in vitro and in vivo
Upon activation of T lymphocytes both, HLA proteins [15] and
TIRC7 [16] cluster at the site of T cell/APC junction. To examine
HLA-DR Alpha 2
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interaction, human PBL were activated with recall antigens for
72 h. Confocal microscopy showed that in recall antigen activated
human lymphocytes both, TIRC7 (green) and HLA-DR (red),
concentrated at the site of the cell – cell interaction. An overlay of
both immunostains suggested a co-localization of both molecules
(yellow) (Figure 5C).
Functional importance of T cell activation through crosslinking
with MHC class II molecules bearing APC is the induction of IL-
12 expression which leads to an increased IFN-c expression in T
cells [4]. IFN-c acts itself as an activator of APC which in turn
induces IL-12 subsequently resulting in inflammation. Data
obtained from our studies indicates that TIRC7 and HLA DR
alpha 2 interaction controls APC - T cell interaction by induction
of negative regulatory signals and prevents an excess of APC - T
cell interaction during immune activation. We therefore hypoth-
esize that triggering TIRC7 signals via sHLA-DRa2 should
suppress the APC - T cell interaction and prevent associated
cytokine release upon stimulation. To prove this hypothesis in
vitro, we used the model of LPS induced APC activation.
Macrophages exposed 48 h to either sHLA-DRa2 or control
protein in the presence of LPS and subsequently subjected to
analysis of cytokine expression via real time PCR method. The
results show a profound reduction of cytokines such as IFN-c,
TNF-alpha, IL-12. Interestingly, chemokines such as MCP-1 and
Rantes were also inhibited indicating that TIRC7-HLA-DR
pathway is controlling T cell and APC specific cytokines after
immune activation (Figure 6A).
Lipopolysaccaride application in mice is characterized by rapid
activation of APC which induces IL-12, endoxinemia and
enhanced cytokine induction such as IFN-c. Of particular
relevance are previous studies in which in vivo neutralization of
IFN-c prevented lethal hypersensitivity reactions to LPS and
reduced IFN-c-dependent lethality [17]. Also, lymphocytes from
mice deficient for IFN-c have been shown to release markedly
reduced amounts of proinflammatory cytokines [18].
Due to immediate activation of APC and T cells, we utilized the
LPS induction model in mice to prove the physiological relevance
of the sHLA-DRa2 targeting of TIRC7 in vivo. First, cross-
reactivity studies were performed using mouse splenocytes and
demonstrated that human sHLA-DRa2 specifically binds to
TIRC7 in mice as shown in microscopic analysis whereas control
Fc did not exhibit any binding (Figure 6B, left panel). Immediately
after the LPS application in vivo, mice were treated with either
sHLA-DRa2 or control protein and splenocytes were subjected to
cytokine analysis. In this study, as assessed by PCR analysis,
Figure 3. TIRC7 targeting leads to cell cycle arrest and apoptosis. A. Human PBL were activated with anti-CD3/CD28 antibodies for 48 h in
the presence of sHLA-DRa2 or control protein (50 mg/ml). The cells were then fixed with 70% ethanol and stained with propidium iodine for cell cycle
analysis using flow cytometry. Incubation with sHLA-DR a2 resulted in a G0/G1 arrest (live cell gate) in comparison to control protein. Shown are
resting cells, PBL activated with anti-CD3/CD28 for 48 h, activated PBL incubated with control protein, and activated PBL incubated with sHLA-DRa2.
B. Human PBL activated with anti-CD3/CD28 were incubated with sHLA-DRa2 or control protein (50 mg/ml) for 48 h and then stained with Annexin V
for the analysis of apoptosis using flow cytometry. When incubated with sHLA-DR a2, human PBL showed a strong increase of Annexin V positive
cells in comparison to control protein. Apoptosis in stimulated cells prior to the administration of either control protein or sHLA-DRa2 protein was
similar in both reactions indicating that the effect on cell cycle distribution and apoptosis was specific. C. Human CD4 and CD8 positive lymphocytes
were separated by magnetic beads and activated with anti-CD3/CD28 antibody for 72 h in the presence of either 50 mg/ml sHLA-DRa2 or Fc control
protein. The cells were subjected to flow cytometry analysis and stained with Annexin V for the detection of apoptosis. Both, CD4+ and CD8+ cell
populations exhibited substantial apoptosis. Shown is one representative experiment out of four independent experiments.
doi:10.1371/journal.pone.0001576.g003
HLA-DR Alpha 2
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the time of intravenous immune challenge with lipopolysaccaride
showed substantially reduced IFN-c, TNF-a, Rantes and IL-6
production 24 h after activation compared with control mice
(Fig 6B, right panel). Thus, treatment with sHLA-DRa2 resulted
in inhibition of inflammation induced via activation of APC and T
cells. Splenocytes of mice were also subjected to western blots for
the analysis of caspase activation. As demonstrated in Figure 6C,
splenocytes exposed to sHLA-DRa2 treatment showed an
increased activation of caspase 7 whereas controls do not exhibit
any activation of caspase 7, indicating that treatment with sHLA-
DRa2 is able to mediate apoptosis in vivo.
Discussion
The beta-2 domain of the conserved HLA-DR alpha molecule
encoded by the HLA-DRA1 locus interacts with the CD4 molecule
in human lymphocytes [19]. The T-cell receptor binds to
polymorphic beta 1 domains of HLA-DR with associated peptide
antigen[20].Othermoleculeswhichbindto HLA-DR include super
antigens such as staphylococcus enterotoxin B (SEB) [21–23], and
toxicshocksyndrometoxin(TSST-1)[24–26].Thesemoleculesbind
to the alpha 1 and beta 1 domains of HLA-DR molecules,
respectively [26]. The ability of SEB to bind many different DR
alleles can be explained by its interaction with the DR alpha 1 chain,
which is conserved in all DR molecules [23]. TSST-1 extends over
nearly half of the binding groove and contacts the alpha helix of the
alpha 1 domain of DR protein [25–27]. The HLA-DR alpha 2
Figure 4. sHLA-DR a2 binds to TIRC7 expressed in CD4 and CD8
T cells. CD4+ and CD8+ T cells were separated by magnetic beads,
stimulated with anti-CD3/CD28 mAb for 48 h, and incubated with
either sHLA-DR a2 or control protein for 30 min prior to confocal
microscopic analysis. Using anti-human Fc-Cy3 mAb as secondary
antibody, binding of sHLA-DRa2 or control protein to TIRC7 protein was
analyzed. The results show a binding in CD4+ and CD8+ human T cells
co-incubated with sHLA-DRa2 (upper panel) whereas no binding was
observed in various control experiments using either control protein
(lower panel) or anti-Fc-Cy3 conjugated secondary mAb only. Shown is
one experiment out of three.
doi:10.1371/journal.pone.0001576.g004
Figure 5. Targeting of TIRC7 in lymphocytes induces apoptosis via the mitochondrial intrinsic pathway. A. PBL were co-incubated
50 mg/ml sHLA-DRa2 or control protein for 5 h, and immunobloting using mAb against caspase 9, caspase 8, caspase 7 and caspase 3 was performed.
Activation of caspase 9 and caspase 7 is indicated by the appearance of cleaved fragments with a size of 37 and 20 kDa, respectively. No activation of
caspase 8 and 3 was observed. B. Human PBL were isolated, activated with anti-CD3/CD28 antibodies (a) cultured in the presence of 50 mg/ml sHLA-
DRa2 (d), and subjected to flow cytometric analysis. In comparison to non-treated controls (b,c) stimulated human T cells incubated with 50 mg/ml
sHLA-DRa2 (d) demonstrated a remarkably reduced expression of FasL as detected by FITC labeled anti-FasL mAb. C. Human PBL were recall antigen
stimulated for 6 days and incubated with FITC labeled anti-TIRC7 mAb. A monocyte cell line, THP-1, was incubated with anti-HLA-DR mAb and
secondary stained with Cy3-conjugate. To increase cell interaction, PBL and THP-1 cells were mixed and incubated at 37uC for 20 min and subjected
to confocal microscopic analysis. The data show that HLA-DR (red color) and TIRC7 (green color) co-localize (merge, yellow color) at the physical site
of T cell/APC interaction. Shown is one experiment out of three.
doi:10.1371/journal.pone.0001576.g005
HLA-DR Alpha 2
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heretofore recognized as a ligand for other molecules.
Several conclusions can be drawn from our work. The first
novel aspect of the work presented here is the identification of the
interaction between HLA-DRa2 and TIRC7, and the demon-
stration of functional relevance of this binding. Soluble HLA-
DRa2 delivers distinct and selective signals via inhibition of IFN-c,
but not IL10 response, strong inhibition of proliferation and
induction of apoptosis. The inhibitory effect observed in the
lymphocyte cultures is solely due to binding between HLA-DR
alpha 2 and TIRC7 as the specific anti-TIRC7 mAb prevents the
inhibition of immune activation.
The second novel aspect of our work relates to the finding that
the HLA-DR protein, beyond its well-known role in initiating
lymphocyte activation by presenting peptides to the TCR
(Figure 4F, left panel) is also able to induce negative signals via
binding of its non-polymorphic alpha 2 domain to TIRC7
(Figure 4F, left panel). This binding is not restricted to CD4+
cells but also includes CD8+ cells and B cells. The findings of
dampening effects on cell activation provided by the HLA-DR
protein and its binding to cell surface molecules other than CD4
and TCR substantially extends the understanding of the regulation
of the immune activation process and the interactions involved. It
is unclear whether the co-localization of both molecules at the site
of cell interaction, as is shown in the present manuscript, may
indicate also cis-acting ligation of TIRC7 and HLA-DR on the
same cell and whether such interaction bears functional relevance.
Our data, however, demonstrate unanimously that the trans-
acting ligation between both molecules induces strong antiprolif-
erative effects in various lymphocyte populations.
The third aspect of this work relates to the finding that the
strong antiproliferative response triggered by TIRC7 ligation is
induced on at least two levels of interference. On the one hand, the
antiproliferative effect is induced by dephosphorylation of early
signaling molecules such as TCR-f and ZAP70 which is associated
with down-regulation of FasL. This result is in accordance with the
fast upregulation of TIRC7 at the cell membrane upon
lymphocyte activation and the clustering of the molecule at the
cell – cell adhesion site [16] where the immunological synapse is
formed [15]. Thus, TIRC7 mediates antiproliferative signals early
in the activation process. On the other hand, the induction of
apoptosis via caspase 9 indicates that the pro-apoptotic pathways
include additional important mechanisms which are orchestrated,
at least in part, by the TIRC7 engagement with HLA-DR alpha 2.
In accordance with this FasL which is the extracellular receptor of
the extrinsic apoptotic pathway via caspase 8 was shown to be
downregulated. After stimulation, in splenocytes obtained from
TIRC7 deficient mice apoptosis was decreased in comparison to
WT splenocytes (unpublished observation) indicating that TIRC7
is central to the induction of apoptosis in lymphocytes. These
results also support the agonistic effect of the compounds used in
this study on the TIRC7-HLA-DRa2 pathway.
The fourth aspect of our work relates to the observation that
binding between HLA-DRa2 and TIRC7 is functional in T cells
Figure 6. TIRC7 signals triggering prevents T cell - APC interaction reflected in inhibition of several cytokines. A. Human PBL were
isolated using standard Ficoll gradient centrifugation protocol and culture 14 days to induce monocyte differentiation. Either sHLA-DRa2 (50 mg/ml)
or control (50 mg/ml) were co-incubated and subjected to cytokine release assays. Cytokine levels were measured by quantitative real time PCR which
revealed a profound inhibition of MCP-1, IL-12, IFN-c, TNF-a and Rantes expression compared with the control. B. Human sHLA-DRa2 showed specific
cross-reactivity on balb/c mice splenocytes (left side). For the in vivo functional analysis balb/c splenocytes were isolated and further subjectedt o
microscopic analysis for cross-reactivity of human sHLA-DRa2 to mouse TIRC7 which resulted in significant binding on activated splenocytes. C. In
balb/c mice (n=14) LPS was administered followed by a single dose (100 mg/mice, i.p.) of human sHLA-DRa2 (200 mg/day, i.p.). Human sHLA-DRa2
resulted in a significant down-regulation of IFN-c, TNF-a and Rantes after 24 h treatment. sHLA-DRa2 or control protein treated splenocytes were
subjected to immunobloting using mAb against caspase 7. Activation of caspase 7 is indicated by the appearance of cleaved fragments with a size of
20 kDa in sHLA-DRa2 treated animals (a1 and a2) whereas no activation of caspase 7 was observed in controls. Shown are two examples out of five.
doi:10.1371/journal.pone.0001576.g006
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macrophages demonstrates that TIRC7-HLA-DR interaction
mediated signals control the expression of proinflammatory
cytokines such as IL-12 which naturally potentiates inflammation
via the induction of IFN-c expression. The data obtained from the
LPS induction in vivo demonstrate that the anti-inflammatory and
apoptotic mode of action of sHLA-DRa2 is physiologically
relevant. The reduction of cytokines such as IL-6, Rantes and
IFN-c in cells obtained from mice treated with HLA-DRa2
indicates that TIRC7 targeting might be potentially translated into
clinical use to prevent acute inflammatory response.
The clinical data and cytokine expression results obtained from
acute inflammatory disease, LPS induction, in mice demonstrate
that treatment with sHLA-DRa2 can control inflammatory
conditions supporting the anti-inflammatory mode of action of
the protein. Accordingly, a substitution of the signal to modulate
TIRC7 pathway using sHLA-DRa2 might lead to a therapeutic
approach unifying both, T cell and APC therapeutic targeting as
TIRC7 is expressed in 30% of all lymphocytes.
In summary, this work provides novel data for the interaction
between HLA-DR alpha 2 and TIRC7 and the functional
relevance of this binding in lymphocytes in vitro and in vivo after
immune activation. For the first time, it is here reported that the
HLA-DR molecule, which is classically described to initiate the
cellular immune response also mediates inhibitory signals and
apoptosis via binding to TIRC7 in lymphocytes, thereby
modulating the decisive first phase of the immune response
(Figure 7). This work introduces HLA-DR as a molecule with a
dual regulatory function in lymphocytes which might have the
potential for the development of novel therapeutic approaches to
treat immune mediated diseases.
Methods
Yeast two-hybrid screen
For bait construction, DNA fragments of TIRC7 containing the
N-terminus (aa 1-173), large extracellular domain (aa 438-512)
and C-terminus (aa 586-614) were amplified by PCR and cloned
into the pBD-GAL4 Cam vector, thereby generating an in-frame
fusion with the GAL4-DNA binding domain. A human PBL
cDNA library was constructed using HybriZAP 2.1 Two-Hybrid
cDNA Library Kit (Stratagene). Standard yeast techniques were
used to manipulate strains. To confirm the observed interaction
the obtained plasmids were tested in MATCHMAKER GAL4-
Two-Hybrid System3 (Clontech).
Immunoprecipitation, Western blot
Lysates from allo-activated PBL and Jurkat cells were incubated
with anti-TIRC7 mAb (20 mg) and mouse IgG as control
(Calbiochem) followed by Western blot analysis using anti-HLA-
DR mAb (CBL120, Cymbus Biotechnology) or anti-TIRC7 mAb.
To analyze phosphorylation of STAT proteins, alloactivated PBL
were incubated with 50 mg sHLA-DR a2 for 4 h. Lysates were
subjected to Western blot analysis using mAb against either anti-
phospho-STAT4 (Ser 721) or (p-STAT4 Santa Cruz, dilution 1/
1000 in 5% BSA/PBS) or STAT4 or STAT6 (Santa Cruz,
dilution 1/1000 in 5% BSA/PBS). To analyze phosphorylation of
TCR-f (Santa Cruz) and ZAP70 (Cell Signaling) PBL were
stimulated with with 100 U/ml IL-2 for 18 h. Western blots were
performed by incubation with a mouse anti-human p-TCR-f
antibody or p-ZAP70. An anti-mouse POD antibody was used for
final analysis in an ECL detection system. For immunoprecipita-
tion studies with SHP1, lysates were incubated for 6h at 4uC with
anti-TIRC7 mAb (20 mg), in the presence of followed by
Figure 7. Scheme of proposed model of regulation of immune activation via TIRC7-HLA-DR alpha 2 binding. TIRC7 serves as ligand for
HLA-DR alpha 2 upon TCR activation in the early phase of immune activation. After positive signals were received and immune cells are activated,
TIRC7 is expressed on the cell surface (A) and its binding to HLA-DR alpha 2 transduces negative signals to lymphocytes (B).
doi:10.1371/journal.pone.0001576.g007
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chem) overnight, at 4uC. Immunoprecipitates were analyzed by
immunoblotting with anti-TIRC7 mAb or anti-SHP1 diluted of
1:200 in 5% milk/PBS and were subjected to chemiluminescent
detection (Amersham Pharmacia). For caspase assays PBL were
seeded at a density of 1,5610E7 cells. sHLA-DR a2 or control
protein were added at a concentration of 50 mg/ml. Cells were
incubated for 6 h, harvested, washed and frozen in liquid nitrogen.
Cell lysis was performed with 50 mM Pipes-HCl, pH 6,5, 2 mM
EDTA, 0,1% CHAPS, 10 mM NaF, 5 mM DTT and protease
inhibitors. Supernatants were boiled with Laemmli-buffer and
subjected to SDS-PAGE. Gels were blotted onto PVDF mem-
branes and analysed using specific antibodies (anti-caspase 8, 9, 3
and 7) (Cell Signaling).
Proliferation and apoptosis assay
For proliferation assay, PBL were obtained from healthy
volunteers after written and informed consent had been obtained.
PBL were isolated according to the Ficoll-Paque density
centrifugation protocol. PBL were labeled by incubation with
CFSE (Carboxyfluorescein succinimidyl ester). The CFSE-labeled
PBL were stimulated with PHA (1 mg/ml, Sigma) or anti-CD3/
CD28 mAb (10 mg/ml) and incubated for 3 days at 5% CO2,a t
37uC in the presence of sHLA-DR a2 or control protein,
respectively, at a concentration ranging between 50–150 mg/ml.
For alloactivation, mixed lymphocytes culture reaction was
performed using donor cells which were inactivated and incubated
with equal cell number of recipient lymphocytes (200.000 total
cells/well) for 72 h at 5% CO2,a t3 7 uC. These cultures were
incubated with either with sHLA-DR a2 or control protein at a
concentration of 50 and 100 mg/ml. The proliferation rate of PBL
was determined by FACS analysis. For proliferation assays,
various human T- and B- cell lines were incubated for 48 h at
37uC, 5% CO2, in the presence of chimeric anti-TIRC7 mAb or
control mAb (50 mg/ml), labelled with 10 ml/well BrdU labelling
solution and incubated for 16 h at 37uC. Cell Proliferation ELISA
BrdU-Kit (Roche Diagnostics GmbH) was used. The measure-
ment of the samples was performed 10–30 minutes after substrate
addition at 370 nm (reference wavelength: 492 nm) in an ELISA
reader. For detection of apoptosis detection, human PBL or cell
lines were stained with 7-AAD for 20 minutes at RT. Samples
were measured and analyzed by flow cytometry.
ELISA cytokine analysis
PBL of human healthy donors isolated according to the Ficoll-
Paque density centrifugation protocol were incubated with 1 mg/
ml PHA (Sigma) in 5% CO2,a t3 7 uC for 48 h in the presence of
sHLA-DRa2 and control protein, respectively. IFN-c or IL-10 was
quantified in supernatants of PHA stimulated cells. Samples were
run in triplicates on 96-well microtiter plates. Cytokine level was
determined using the CytoscreenH ELISA Kit (Biosource).
Flow cytometry and confocal microscopy
Splenocytes from wild type (WT) and TIRC7(-/-) mice were
isolated with a cell strainer and transferred to 15 ml tubes. Cells
were stimulated with 4 mg/ml ConA (Sigma) for 14–16 h and
permeabilized with Perm-solution2 (BD biosciences) and Fc-
blocked for 30 min at 4uC. After incubation with 8 mg/ml HLA-
DR Fc or control protein for 30 min, cells were secondary stained
with anti-human Cy3 (Sigma) (1:250) and analyzed via FACS
Calibur (BD Biosciences). Isolated human PBL (5610
5 cells/well)
were incubated with 50 mg/ml soluble HLA-DR alpha 2 or
control protein. After 72 h or 5 h of incubation the cells were
washed with FACS-buffer and stained with 2,5 ml FAS-L-PE or
caspase 7 (BD Biosciences) or mIgG-PE as control for 30 min at
RT. Immunofluorescence analysis were performed using standard
protocols. All images were taken using LSM 510 confocal laser
microscope (ZEISS).
Expression of TIRC7-myc fusion protein and sHLA-DR a 2-
Fc fusion protein in COS7 cells
TIRC7-myc fusion protein [1] was expressed in COS7 cells after
transient transfection with a pCDNA3 construct containing an
expression cassette for TIRC7-myc fusion protein using Fugene6
Transfection Reagent (Roche). For HLA-DR alpha 2 expression
in mammalian expression system the HLA-DR alpha 2 domain
was fused to IgG1-Fc fragment. COS7 cells were transiently
transfected with vector and after 96 h the fusion protein was
purified by Sepharose A column from cell culture supernatants.
Real time PCR
PML were separated from buffy coats of healthy donors by
centrifugation on a Ficoll-Paque density gradient and monocytes
were purified by adherence. After 14 days, we stimulated
monocytes with 5 mg/ml LPS and 200 u/ml IL-4 and incubated
them with 50 mg/ml HLA-DR-Fc or control for 2 days. RNA was
extracted using RNeasy Mini Kit (Qiagen). cDNA was synthesized
from mRNA with random hexamers and TaqMan reverse
transcriptase (Applied Biosystems). Reactions use specific primers
and Sybr Green PCR Master Mix (Applied Biosystems) or specific
probes (TaqMan Gene Expression Assay, Applied Biosystems),
detected by use of an ABI Prism 7300 Sequence Detection System
(Applied Biosystems). To standardize results, we expressed them as
the number of target gene copies per 10
5 copies of 18S-rRNA.
LPS and induction in mice
Balb/C mice (10–14 weeks old) were induced intraperitoneally
with 50 mg LPS on day 0. Immediately afterwards 14 mice were
treated intraperitoneally with either sHLA-DR a2-Fc (200 mgi n
PBS) or human Fc as control (200 mg in PBS), respectively. After
24 h, spleens were removed for further cytokine analysis via
FACS.
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